single Genomic Test Can Diagnose Nearly Any Infection
On Nov. 12, 2024, researchers from the University of California, San Francisco (UCSF) reported that their genomic test…
4-strain meningococcal vaccine tied to reduction in invasive meningitis cases, deaths
On Nov. 7, 2024, researchers reported that Implementation of routine immunization of U.S. adolescents with the quadrivalent (four-strain)…
FDA approved PENBRAYA,the first and only vaccine for prevention of most common serogroups causing meningococcal
On Oct. 20, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved PENBRAYA (meningococcal…
CDC’s ACIP recommended routine vaccination with a quadrivalent meningococcal conjugate vaccine for adolescents aged 11 or 12 years, with a booster dose at age 16 years.
On Sept. 25, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination with a quadrivalent meningococcal…
World’s first meningitis B national infant vaccination programme showed 75% drop in cases over three years
On Jan. 23, 2020, two independent meningitis B studies were published in the New England Journal of Medicine…
Biotechnology | CDC | Disease | Life Science News | NIH | Non-Profit Research | Therapeutics | Vaccine
CDC published ACIP’s updated recommendations on use of Trumenba meningococcal serogroup B vaccine
On May 19, 2017, the U.S. Centers for Disease Control and Prevention (CDC) published Immunization Practices Advisory Committee…
Biotechnology | CDC | Disease | HIV | Life Science News | Non-Profit Research | Pharmaceutical | Vaccine
CDC published ACIP recommendations for use of meningococcal conjugate vaccines in HIV-infected persons
On Nov. 4, 2016, the U.S. Centers for Disease Control and Prevention’s (CDC) Immunization Practices Advisory Committee (ACIP)…
FDA approved the use of Bexsero, the second vaccine licensed in the U.S. to prevent serogroup B meningococcal disease
On Jan. 23, 2015, Novartis announced the US Food and Drug Administration (FDA) had granted accelerated approval of…
Biotechnology | CDC | Disease | Life Science News | NIH | Non-Profit Research | Therapeutics | Vaccine
CDC published ACIP’s recommendations for use of MenACWY-CRM vaccine in children age 2-23 months at increased risk for meningococcal disease
On Jun. 20, 2014, the U.S. Centers for Disease Control and Prevention (CDC) published Immunization Practices Advisory Committee…
FDA expanded age indication for Menveo to include infants and toddlers age 2 through 23 months
On Aug. 1, 2013, Novartis announced the U.S. Food and Drug Administration (FDA) had approved Menveo (Meningococcal [Groups…
Biotechnology | Disease | FDA | Life Science News | Vaccine
FDA approved HibMenCY vaccine for infants
On Jun. 24, 2012, the U.S. Food and Drug Administration (FDA) announced it had approved HibMenCY (Menhibrix, GlaxoSmithKline),…
FDA approved the first vaccine to prevent meningococcal disease in infants and toddlers
On Apr. 22, 2011, The U.S. Food and Drug Administration (FDA) approved the use of Menactra in children…
FDA approved licensure of Menveo (Novartis), meningococcal conjugate vaccine
On Feb. 19, 2010, the U.S. Food and Drug Administration (FDA) announced it had licensed a quadrivalent meningococcal…
CDC published updated recommendation for meningococcal vaccination of at-risk children age 2-10 years in MMWR
On Oct. 17, 2007, the Food and Drug Administration (FDA) approved quadrivalent meningococcal conjugate vaccine (MCV4) (Menactra®, Sanofi…
Sanofi Pasteur announced FDA approval of Menactra meningococcal conjugate vaccine indication for infants
On Apr. 22, 2005, Sanofi Pasteur announced the U.S. Food and Drug Administration (FDA) had granted licensure to…
The Bill and Melinda Gates Foundation earmarked $70 million to develop and produce meningitis vaccines
In 2001, The Bill and Melinda Gates Foundation earmarked $70 million to develop and produce meningitis vaccines tailored…
A meningococcal group C conjugate vaccine was introduced into the routine schedule in the UK
In 1999, a meningococcal group C conjugate vaccine was introduced into the routine schedule in the U.K. for…
Quadrivalent groups A, C, Y, and W-135 (Menomune A/C/Y/W-135 by Connaught) meningococcal vaccine was licensed
On Nov. 23, 1981, the U.S. Food and Drug Administration licensed Quadrivalent groups A, C, Y, and W-135…
Monovalent group A, group C meningococcal vaccines, and a bivalent vaccine for both groups A and C were licensed
On Jan. 3, 1978, the U.S. Food and Drug Administration (FDA) licensed the Monovalent group A (Menomune-A by…
The first monovalent (group C) meningococcal polysaccharide vaccine (Merck) was licensed
On Apr. 2, 1974, the U.S. Food and Drug Administration (FDA) licensed the first monovalent (group C) meningococcal…
Margaret Pittman showed precipitin reaction around meningococcus colonies on immune serum was correlated with mouse potency assay
In 1938, Margaret Pittman showed that the precipitin reaction around meningococcus colonies on immune serum agar plates was…
Margaret Pittman, Sara E. Branham, and E. M. Sockrider showed type specificity of meningococcus by use of the Petrie’s precipitin test
In 1937, Margaret Pittman, Sara E. Branham, and E. M. Sockrider showed the type specificity of meningococcus by…
Sara Branham identified a new organism, Neisseria flavescens, as a rare cause of meningitis and septicemia in humans
In 1930, Sara E. Branham identified a new organism, Neisseria flavescens, as a rare cause of meningitis and…